QUARTERLY REPORT Q3 2025
SIGNIFICANT EVENTS DURING 1 JULY – 30 SEPTEMBER 2025During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term…
Iconovo reworks its strategic goals
Iconovo AB (publ), a leading company in the development of inhalable medicines based on proprietary inhalers and dry powder formulations, today announces that it is leaving the financial targets communicated on June 1, 2022. The goals are under revision and will focus on optimizing the value and commercialization of the company's fully developed inhalers, as well as the development of an intranasal version of the best-selling GLP-1 analogue semaglutide. The purpose of the recent organizational change was to further strengthen this direction.
Iconovo AB changes Certified Adviser to Tapper Partners AB
Iconovo AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.
QUARTERLY REPORT Q2 2025
SIGNIFICANT EVENTS DURING 1 APRIL – 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately…
Iconovo’s rights issue is registered – conversion of BTA into shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG,…
Iconovo’s development of intranasal GLP-1 for a more convenient treatment of obesity is making significant progress
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announce that the development of spray-dried formulations of intranasal GLP-1 is making significant progress. Iconovo has obtained several batches of formulations from its partner Lonza and begun feasibility studies in ICOone Nasal®. Data shows impressive and consistent capabilities suitable for nasal inhalation.
Iconovo’s nomination committee proposes the election of Christer Fåhraeus as new board member
Iconovo AB today announces that the company's Nomination Committee has decided to revise its proposal for the annual general meeting to be held today 9 June 2025 by proposing that Christer Fåhraeus is elected as a new member of the Board of Directors in addition to the Board members previously proposed. The background for the revision is that the Nomination Committee has been informed that FSG Fund II AB ("FSG") has participated in the recently completed rights issue and that FSG, after final registration of the rights issue, will hold approximately 15.5 per cent of the shares and votes in Iconovo.
Iconovo announces final outcome in the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Iconovo announces preliminary outcome of rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Last day of trading in subscription rights in Iconovo
Today, 27 May 2025, is the last day of trading in the subscription rights issued in conjunction with Iconovo AB (publ)'s (“Iconovo” or the “Company”) rights issue of shares with pre-emption rights for existing shareholders resolved by the Board of Directors on 24 April 2025, and approved by the Extraordinary General Meeting on 12 May 2025 (the “Rights Issue”). Subscription rights that are not sold by today, 27 May 2025, or exercised for subscription of shares no later than 2 June 2025, will expire without value.
